Search results
Results from the WOW.Com Content Network
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. [1] It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid , or have HIV/AIDS .
Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. [2] During childhood, five doses are recommended, with a sixth given during adolescence. [2] After three doses, almost everyone is initially immune, [2] but additional doses every ten years are recommended to maintain immunity. [3]
Serum horses proved to be saviors of diphtheria-infected people. Subsequently, treatment of tetanus, rabies, and snake venom developed, and proactive protective vaccination against diphtheria and other microbial diseases began. In 1901, Behring won the first Nobel Prize in Medicine for his work in the study of diphtheria.
Tetanus immunoglobulin (TIG), [1] also called tetanus antibodies or tetanus antitoxin. [45] It can be given as intravenous therapy or by intramuscular injection. Antibiotic therapy to reduce toxin production. Metronidazole intravenous (IV) is a preferred treatment. [47] Benzodiazepines can be used to control muscle spasms.
Multiple doses of tetanus toxoid are used by many plasma centers in the United States for the development of highly immune persons for the production of human anti-tetanus immune globulin (tetanus immune globulin (TIG), HyperTet (c) [5]), which has replaced horse serum-type tetanus antitoxin in most of the developed world.
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Between 1889 and 1895, Behring developed his pioneering ideas on serum therapy and his theory of antitoxins. [3] Early 1887, in Bonn, Behring had found that the serum of tetanus-immune white rats contained a substance that neutralized anthrax bacilli. He recognized this as the source of their "resistance". [3]
During the 1960s and 70s, Biological E developed formulations in cough and digestive enzymes, started manufacturing anti-tetanus serum, and launched anti-TB drugs, TT and DTP vaccines. [5] Biological E embarked specialise in low-cost vaccines manufacturing.